What does it do?
Mirion Technologies is a growth business that earns money by designing and selling specialized sensors, software, and services used to detect and measure ionizing radiation. It operates two primary segments: Nuclear and Medical. In the nuclear sector, the company sells equipment for power plant monitoring, laboratory research, and defense, typically charging a high upfront price for hardware followed by decades of recurring maintenance and calibration fees. In the medical sector, it provides quality assurance tools and dosimetry services that ensure cancer treatments are delivered safely and healthcare workers are not overexposed to radiation.
Where does revenue come from?
The majority of revenue comes from high-precision hardware sales, but recurring service and software contracts provide a stable profit base. Its Product segment accounted for $204.3 million in the most recent quarter, while Service revenue added $62.5 million. The Nuclear segment is the largest contributor, particularly following the acquisition of Paragon Energy Solutions, which focuses on parts and services for the existing global nuclear reactor fleet.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Mirion Technologies serves approximately 3,200 large-scale customers including nuclear power operators, oncology clinics, and government defense agencies. The company manages radiation safety for hundreds of nuclear power plants globally and provides dosimetry services to thousands of medical professionals. It reported total orders of $291 million in the second quarter of 2026, which included a 40% year-over-year increase when acquisitions are factored in. Its customer base is characterized by high switching costs because switching providers often requires re-certifying equipment with federal regulators.
What gives it staying power?
Staying power comes from the deep regulatory integration of its products into nuclear facilities and healthcare workflows. Once a Mirion sensor is designed into a nuclear plant or a cancer clinic, it is very difficult to replace because the cost of regulatory re-approval far outweighs the cost of the equipment.
Where is it headed?
The company is making a major strategic bet on the revitalization of the North American nuclear energy market through acquisitions and partnerships. Management recently formed a strategic partnership with Perma-Fix to target federal nuclear cleanup contracts and is positioning the company to be a primary supplier for the emerging Small Modular Reactor industry.
Revenue is growing at a double-digit pace as the company integrates major acquisitions and benefits from a 10% organic increase in underlying orders. Total revenue reached $266.8 million in the most recent quarter, reflecting a 19.7% jump that shows the company is successfully capturing the rising demand for nuclear safety equipment.
Cash generation is healthy and improving, with adjusted free cash flow projected to reach as much as $175 million for the full year 2026. Free cash flow tracked behind net income in the first half of the year due to seasonal inventory builds, but management expects a conversion rate of over 54% of its adjusted operating profits by year-end.
The balance sheet is leveraged following recent acquisitions, but the company maintains a comfortable cash cushion of $418.7 million to fund its operations. While Mirion carries roughly $1.2 billion in total debt, including convertible notes, its net leverage is manageable given the high visibility of its recurring service contracts and growing order backlog.
Mirion is a financially resilient business that is successfully pivoting from a heavy investment phase into a period of consistent, high-margin cash generation.
Mirion does not pay a dividend, but it is actively using its cash to buy back shares and fund strategic acquisitions. The company spent $41 million on buybacks in the first half of 2026, and the total share count has decreased by roughly 0.6% since the start of the year. This indicates that management is focused on offsetting employee stock grants and slowly growing each owner's slice of the business.
Organic order growth reached 10% in the most recent quarter, proving that demand for radiation monitoring is strong even without the boost from new acquisitions. This growth is being driven by the nuclear power segment, which is seeing higher activity as existing plants extend their operating lives.
The integration of the $590 million Paragon acquisition is the primary execution risk for management over the next year. If the company fails to capture the expected operational synergies, it could struggle to meet its ambitious 25% adjusted profit margin target for 2026.
The global radiation detection and monitoring market is roughly $5 billion today and is on track to reach $7 billion by 2029 as nuclear power expansions and advanced cancer therapies drive demand. This is a rationally structured industry where regulatory hurdles prevent a race to the bottom on price. Mirion stands as a dominant leader in this niche, particularly in the nuclear safety segment where its technology is deeply embedded in the world's reactor fleet.
The competitive dynamic is characterized by high barriers to entry and long-term contracts that favor established incumbents. Winning new business depends more on technical certification and safety records than on aggressive price cutting.
The main competitors are large industrial conglomerates like Thermo Fisher and specialized safety firms like Landauer. Thermo Fisher's massive scale allows it to bundle radiation tools with broader lab equipment, making it the primary threat in the medical and research segments. Landauer competes directly for the recurring fees paid by hospitals to monitor employee radiation exposure.
Mirion is successfully gaining share in the nuclear aftermarket, as evidenced by its 40% surge in total orders following recent strategic acquisitions.
The primary source of protection is switching costs created by federal safety regulations. In the nuclear and medical industries, equipment must be certified by government agencies, and switching to a new sensor provider requires a costly and time-consuming re-approval process. This creates a captive customer base for Mirion's high-margin replacement parts and maintenance services.
Financial metrics like the 48% gross margin and the high proportion of service revenue prove the strength of this advantage. The company's ability to maintain these margins while growing orders at double-digit rates indicates that it possesses genuine pricing power in its core markets.
The moat is strengthening. The acquisition of Paragon gives Mirion a tighter grip on the supply chain for existing nuclear plants, ensuring its technology remains the standard for the next generation of maintenance cycles.
Reaffirmed 2026 guidance after a 16% EPS beat in the most recent quarter.
Completed the $590M Paragon acquisition and spent $41M on buybacks this year.
Thomas Logan is the founder and holds a significant multi-million dollar equity stake.
Capital Allocation Track Record
Thomas Logan has demonstrated exceptional leadership by successfully transitioning Mirion from a private entity into a public growth business while maintaining steady organic growth. Management has earned credibility by consistently hitting its financial targets and making disciplined acquisitions that expand the company's competitive moat in the nuclear energy sector. The decision to spend $41 million on buybacks while also funding a major acquisition shows a sophisticated approach to managing the balance sheet and returning value to shareholders.
The primary governance risk is the high level of key-person dependence on Thomas Logan, who serves as both the CEO and Chairman. While there is a deep bench of group presidents running the individual segments, Logan's vision has been the primary driver of the company's aggressive M&A strategy. There is no immediate evidence of board independence concerns, but any sudden change in leadership could create temporary uncertainty regarding the company's long-term strategic direction.
We expect revenue to grow from $1.1B in FY2026 to $1.6B in FY2031 (~7% CAGR), with EPS growing from $0.54 to $1.20 (~17% CAGR). Growth is driven by the global expansion of nuclear power facilities and increasing demand for radiation safety in medical procedures. Profitability improves as the company moves past its initial restructuring phase and spreads its specialized engineering costs over a larger volume of sensor sales. EPS grows significantly faster than revenue because the company is aggressively buying back shares while simultaneously expanding its profit margins. Operating margin expected to reach ~18% by FY2031.
Nuclear plant life extensions drive multi-decade maintenance and upgrade cycles. Governments extending the life of current nuclear plants creates a high-margin recurring revenue stream for Mirion's certified parts.
Small Modular Reactor adoption creates a new market for sensor design-ins. As SMRs move from design to construction, Mirion is positioning its sensors to be the factory standard for these new fleets.
Medical oncology growth expands high-margin dosimetry and QA service revenue. Global investment in cancer treatment centers increases the demand for the precision calibration and monitoring tools Mirion provides.
Global nuclear safety event triggers a shift away from nuclear energy. A major accident anywhere in the world could lead governments to pause or cancel nuclear projects, stalling Mirion's growth.
Integration failure of the Paragon acquisition leads to margin compression. If management fails to capture operational synergies, the debt used to fund the deal could become a burden on cash flows.
Rising interest rates increase the cost of servicing convertible debt. A sustained period of high rates could make it more expensive for Mirion to refinance its $1.2 billion in total debt.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We value Mirion using a model that looks at its expected earnings in five years and discounts them back to today. Because Mirion has just recently become profitable after years of building its scale, looking only at next year's earnings would miss the long-term potential of its recent acquisition and the move toward more nuclear power.
A $1.20 profit in 2031 multiplied by a 25x price-to-earnings ratio gives a future value of $30, which is worth $20 in today's dollars. Its rivals like Fortive and Thermo Fisher trade between 20x and 35x; we used 25x to reflect Mirion's strong growth but also its higher debt load. This $1.20 estimate comes from our long-term projection of the business, and we used a 10% discount rate to account for the risk and the time it takes for those profits to arrive.
If we price the company based on next year's expected earnings instead, we get a value of $16.50 per share. This uses the $0.66 per share analysts expect for 2027 and applies the same 25x multiple its rivals trade for. This value is within 20% of our $20 target and sits very close to where the stock trades today, which confirms our long-term math is reasonable. We trust the $20 figure more because it accounts for the full benefits of the recent Paragon acquisition that won't be completely visible until 2028.
The biggest risk is the heavy debt load taken on to fund the Paragon acquisition. This $1.23 billion in debt could force the fair value down toward $11 if interest rates stay high or the expected savings from the deal never arrive. Watch the interest payment costs in the next two reports; if they keep eating most of the profit, the price for each dollar earned will likely drop from 25x to 15x.
Bear case ($12): Organic revenue growth falls below 3% as government delays in nuclear medicine orders persist through 2027; or Interest payments on the $1.23 billion debt load consume more than 60% of quarterly operating income.
Bull case ($28): Adjusted EBITDA margins climb toward 28% as the Paragon acquisition provides higher-margin software services; or New federal nuclear cleanup contracts with Perma-Fix contribute over $100 million in first-year revenue.
Clearthesis wrote this report from 40 sources, including SEC filings, analyst estimates, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on September 2, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.